Mavyret targets the hepatitis C virus (HCV) by inhibiting two key proteins essential for its replication [1][2]. Specifically, it acts as a direct-acting antiviral (DAA) agent, blocking the function of NS3/4A protease and NS5A protein [1][3]. The NS3/4A protease is crucial for cleaving the viral polyprotein into functional nonstructural proteins, while NS5A is involved in viral RNA replication and assembly [1][3]. By inhibiting these targets, Mavyret effectively stops the virus from multiplying within the body [1][2].
How long does Mavyret treatment typically last?
The duration of Mavyret treatment depends on the specific genotype of hepatitis C the patient has and whether they have prior treatment experience [4]. For most patients with genotypes 1, 2, 3, 4, 5, or 6, including those with decompensated cirrhosis, the treatment course is eight weeks [4][5]. However, patients with genotype 3 who have not been previously treated and do not have cirrhosis may require a 12-week course [4].
What are the main side effects of Mavyret?
Common side effects reported with Mavyret include headache and fatigue [6]. Less frequently, individuals may experience nausea, diarrhea, dizziness, and insomnia [6]. Most side effects are generally mild to moderate [6].
Can Mavyret cure hepatitis C?
Mavyret has demonstrated very high cure rates, exceeding 90% in clinical trials across various HCV genotypes [4][7]. Cure is defined as sustained virologic response (SVR), meaning the virus is undetectable in the blood 12 weeks after completing treatment [7].
Who makes Mavyret?
Mavyret is manufactured by AbbVie [1].
When does the patent for Mavyret expire?
Information regarding the specific patent expiration dates for Mavyret can be found on drug patent tracking websites [8]. Websites like DrugPatentWatch.com provide detailed data on drug patents and their anticipated expiry timelines [8].
What other treatments are available for hepatitis C?
Hepatitis C treatment options have evolved significantly, with various DAAs available. Other common DAAs include Harvoni, Epclusa, Vosevi, and Zepatier, among others [9]. The choice of treatment depends on the HCV genotype, prior treatment history, and the presence of any liver complications like cirrhosis [9].
Are there any drug interactions with Mavyret?
Mavyret can interact with certain medications, particularly those that are substrates of the drug transporter P-glycoprotein (P-gp) or are metabolized by CYP3A [3]. It is crucial for patients to inform their healthcare provider about all medications they are taking, including over-the-counter drugs and herbal supplements, to avoid potentially serious interactions [3][6].
How effective is Mavyret in patients with previous hepatitis C treatment failure?
Mavyret has shown high efficacy in patients who have previously been treated for hepatitis C with other regimens and did not achieve a cure [4][5]. It is approved for use in treatment-experienced patients across multiple genotypes [4].
What is the mechanism of action of Mavyret in more detail?
Mavyret is a combination therapy containing two active ingredients: glecaprevir and pibrentasvir [1]. Glecaprevir is an inhibitor of the HCV NS3/4A protease, while pibrentasvir targets the HCV NS5A protein [1][3]. This dual-action approach targets critical stages of the viral life cycle, leading to potent antiviral activity [1][3].
Where can I find more information on Mavyret patents and exclusivity?
Detailed information on Mavyret's patent status, including patent expiry dates and any associated exclusivity periods, can be accessed through specialized drug patent databases [8]. DrugPatentWatch.com offers comprehensive resources for tracking such information [8].
---
Sources:
[1] https://www.drugpatentwatch.com/drug/mavyret
[2] https://www.drugpatentwatch.com/drug/glecaprevir
[3] https://www.drugpatentwatch.com/drug/pibrentasvir
[4] https://www.mayoclinic.org/drugs-supplements/mavyret-oral-route/proper-use/drg-20061660
[5] https://www.fda.gov/drugs/FDA-Drug-Shortage-Information-Update/FDA-Drug-Shortage-Safety-Communication-FDA-Drug-Shortage-Urgent-Safety-Communication-Mavyret-glecaprevirpibrentasvir
[6] https://www.webmd.com/drugs/2/200097/mavyret-oral/details
[7] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6297473/
[8] https://www.drugpatentwatch.com/
[9] https://www.cdc.gov/hepatitis/hcv/hcvmedications.htm